5 (Plus Project) Facts You Didn’t Know – PSI’s Impact on Malaria Chemoprevention

By Meredith Center, Plus Project Director, PSI and Malia Skjefte, Malaria Technical Advisor, PSI

Everyone loves a fun fact (and that’s a fact).

After decades of steady decline, malaria cases have seen a resurgence over the last few years, with an estimated 247 million cases in 2021 compared to 245 million cases in 2020. To counteract this recent rise in malaria incidence, PSI strives to strengthen the health systems that deliver malaria care and address the critical gaps that persist in testing and treatment practices. We begin with the needs of consumers and then work closely with governments, strategic partners, and other key stakeholders to address their unique perspectives.

As part of our official launch, we’re highlighting key facts about the Plus Project, a Unitaid-funded initiative led by PSI to co-design, implement, and evaluate country-adapted models of Perennial Malaria Chemoprevention (PMC). Recommended by the World Health Organization (WHO) as part of its malaria chemoprevention strategies, PMC is targeted at children in areas of year-round, moderate to high malaria transmission.

The Plus Project works in close collaboration with National Malaria Control Programs (NMCPs) to develop and implement PMC in four African countries, and to collect evidence on impact, effectiveness and cost-effectiveness. Implementation experience and research evidence from the project will be shared with national, regional and global stakeholders aiming to support the adoption and scale-up of PMC in the focus countries and other malaria-endemic countries of sub-Saharan Africa, including through revisions to national policies and guidelines.

Now, to the facts of how we are designing PMC to be cost-effective and sustainable:


In 2022, the WHO updated its Guidelines for malaria to include PMC as a key chemoprevention intervention. This expands on and replaces the previous recommendation of Intermittent Preventive Treatment in infants (IPTi) using the combination medication, Sulfadoxine-Pyrimethamine (SP).

The updated guidance includes changes to the dosing schedule, age requirements, and considerations for drug resistance. While the previous guidelines recommended three doses of SP at predefined intervals of ten weeks, 14 weeks, and nine months old — to be timed with routine childhood vaccinations — the updated recommendation removes this strict specification on the number and timing of doses for PMC. Additionally, the recommended target age group extended to include children even older than one-year, furthering SP’s preventative impact.

As new evidence demonstrates the effectiveness of SP, even in areas with high parasitic resistance, the updated guidance removes previous restrictions on using SP based on resistance thresholds. This expands the possible geographies where PMC can be implemented, prompting countries to make decisions on use based on available evidence.


The project takes place across four focus countries: Cameroon, Benin, Côte d’Ivoire, and Mozambique. We will also collect limited data in three additional countries — Democratic Republic of Congo, Ghana, and Zambia — that are interested in the adoption and scale-up of PMC.

While the target group for our intervention are all children under two years, the total number of target doses of SP to be delivered varies by country ranging from four to eight doses. Dosages are delivered leveraging existing vaccine, vitamin A, and routine child visits to health facilities, as well as through community delivery in Cameroon. The different models of PMC with varying dosing schedules and channels will allow research studies to inform future decisions about when and how to implement PMC.


Community stakeholders range from the caregivers of the children receiving PMC to community health workers, providers, local government officials, community leaders, and staff of National Malaria Control Programs and Expanded Programs on Immunization. Underpinning these PMC activities are in-depth training sessions, routine monitoring, supervision, and community engagement activities, which are currently being integrated into existing country systems. We also helped establish country Advisory Groups, which advise, monitor, and support the PMC activities and research for maximum benefit and a view towards sustainability and full government ownership.


The project’s approach to collaborative design reflects the shift to provide greater flexibility to NMCPs to adapt control strategies to suit their settings. The Plus Project partners with governments and other key stakeholders to design country-specific models of PMC for their context, including the number and timing of SP doses as well as the delivery channel. The PMC models in each focus country have been co-designed with key stakeholders of those countries and are a product of country-led ideation and decision-making. We use a customized evaluation approach with each focus country to generate data for policy work and decision-making.

The evaluations are led by the London School of Hygiene and Tropical Medicine (LSHTM) in collaboration with country research partners, including the Centre de Recherche Entomologique de Cotonou (CREC) in Benin, the Fobang Institutes for Innovations in Science and Technology (FINISTECH) in Cameroon, the Institut National de Santé Publique (INSP) in Côte d’Ivoire, and the Centro de Investigação em Saúde de Manhiça (CISM) in Mozambique, as well as the University of Copenhagen who is contributing to the genotyping work.


Children have already begun to receive SP in Plus Project countries. The first dose of SP for PMC was delivered in Côte d’Ivoire in November 2022 and as of February 2023, the other three Plus Project countries have started their distribution. The project launch is successfully underway.


Over the next four years, we will release numerous communications materials featuring learnings, results, and insights from the project. For now, we invite you to stay up to date on our progress by visiting the Plus Project’s website where we provide resources, country updates, and perspectives from our partners: https://www.psi.org/project/plusproject/

…And don’t worry, there are more fun facts to come.

Infant receiving first dose of SP during routine vaccine visit at the CSU Appoisso health facility in Abengourou, Côte d'Ivoire (January 2023)

Feature Photo Credit: Malika Kounkourou, Princeton in Africa Fellow

Sign up to
Receive Updates

Donate to
Support Our Work



The Future of Work

With overarching commitments to flexibility in our work, and greater wellbeing for our employees, we want to ensure PSI is positioned for success with a global and holistic view of talent. Under our new “work from (almost) anywhere,” or “WFAA” philosophy, we are making the necessary investments to be an employer of record in more than half of U.S. states, and consider the U.S. as one single labor market for salary purposes. Globally, we recognize the need to compete for talent everywhere; we maintain a talent center in Nairobi and a mini-hub in Abidjan. PSI also already works with our Dutch-based European partner, PSI Europe, and we’re creating a virtual talent center in the UK.


Meaningful Youth Engagement

PSI is firmly committed to the meaningful engagement of young people in our work. As signatories of the Global Consensus Statement on Meaningful Adolescent & Youth Engagement, PSI affirms that young people have a fundamental right to actively and meaningfully engage in all matters that affect their lives. PSI’s commitments aim to serve and partner with diverse young people from 10-24 years, and we have prioritized ethics and integrity in our approach. Read more about our commitments to the three core principles of respect, justice and Do No Harm in the Commitment to Ethics in Youth-Powered Design. And read more about how we are bringing our words to action in our ICPD+25 commitment, Elevating Youth Voices, Building Youth Skills for Health Design.


Zero Tolerance for Modern-Day Slavery and Human Trafficking

PSI works to ensure that its operations and supply chains are free from slavery and human trafficking. Read more about this commitment in our policy statement, endorsed by the PSI Board of Directors.



Since 2017, PSI has been a signatory to the United Nations Global Compact, a commitment to align strategies and operations with universal principles of human rights, labor, environment and anti-corruption. Read about PSI’s commitment to the UN Global Compact here.


Environmental Sustainability

The health of PSI’s consumers is inextricably linked to the health of our planet. That’s why we’ve joined the Climate Accountability in Development as part of our commitment to reducing our greenhouse gas emissions by 30 percent by 2030. Read about our commitment to environmental sustainability.


Affirmative Action and Equal Employment Opportunity

PSI does not discriminate against any employee or applicant for employment because of race, color, religion, sex, sexual orientation, gender identity, national origin, age, marital status, genetic information, disability, protected veteran status or any other classification protected by applicable federal, state or local law. Read our full affirmative action and equal employment opportunity policy here.


Zero Tolerance for Discrimination and Harassment

PSI is committed to establishing and maintaining a work environment that fosters harmonious, productive working relationships and encourages mutual respect among team members. Read our policy against discrimination and harassment here.

PSI is committed to serving all health consumers with respect, and strives for the highest standards of ethical behavior. PSI is dedicated to complying with the letter and spirit of all laws, regulations and contractual obligations to which it is subject, and to ensuring that all funds with which it is entrusted are used to achieve maximum impact on its programs. PSI provides exceptionally strong financial, operational and program management systems to ensure rigorous internal controls are in place to prevent and detect fraud, waste and abuse and ensure compliance with the highest standards. Essential to this commitment is protecting the safety and well-being of our program consumers, including the most vulnerable, such as women and children. PSI maintains zero tolerance for child abuse, sexual abuse, or exploitative acts or threats by our employees, consultants, volunteers or anyone associated with the delivery of our programs and services, and takes seriously all complaints of misconduct brought to our attention.


Diversity and Inclusion

PSI affirms its commitment to diversity and believes that when people feel respected and included they can be more honest, collaborative and successful. We believe that everyone deserves respect and equal treatment regardless of gender, race, ethnicity, age, disability, sexual orientation, gender identity, cultural background or religious beliefs. Read our commitment to diversity and inclusion here. Plus, we’ve signed the CREED Pledge for Racial and Ethnic Equity. Learn more.


Gender Equality

PSI affirms gender equality is a universal human right and the achievement of it is essential to PSI’s mission. Read about our commitment to gender equality here.


01 #PeoplePowered

02 Breaking Taboos

03 Moving Care Closer to Consumers

04 Innovating on Investments

Let's Talk About Sex